Bullish & Foolish
Full NXTC fundamentals All 466 on the Survival Watch

NXTCNextCure, Inc.

Is NextCure struggling financially?

Yes, by its own account. NextCure told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$28.8M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$15.3M

÷

Cash burned over the last 12 months

$86.1M

What NextCure told the SEC

…incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued. See Note 2, Summary of Significant Accounting Policies, for a further assessment of…

NextCure, Inc., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 124.0% share-count increase The company issued stock. Each share now owns 55.4% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt